Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 195 participants.
Also called NCT05682378
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 195 participants
- Sponsor
- Registry
-
NCT05682378 -
2022-002316-23
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Brazil, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Jordan, Lebanon, Malaysia, Netherlands, Norway, Poland, Russia, Slovakia, Slovenia, South Africa, Spain, Switzerland, Taiwan, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT05682378. Allocation not applicable; no masking; primary purpose treatment. Start 2023-02-10 (actual); primary completion 2032-03-25 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
- Acronym
- V-PEDS-OLE
- Condition
- Heterozygous or Homozygous Familial Hypercholesterolemia
- Intervention (Drug)
- Inclisiran
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05682378- Content hash
920178ad5798fe47574ca2ec71c216f859dd98a0238392206f5a06752a353e25